Results 191 to 200 of about 35,993 (244)

CYP2C19 genotype-guided escalation to ticagrelor vs. clopidogrel in secondary stroke prevention: a retrospective cohort study. [PDF]

Front Pharmacol
Haidong S, Min D, Hong Y, Jing Y.
europepmc   +1 more source

Ticagrelor Resistance Causing Acute In-Stent Thrombosis: Successful Management With Prasugrel and Balloon Angioplasty. [PDF]

J Med Cases
Jia K, Rimsky E, Sattarzadeh A, Pradeep AG, Amor MMI.   +4 more
europepmc   +1 more source

Characterization of Novel Variants in <i>P2YRY12, GP6</i> and <i>TBXAS1</i> in Patients with Lifelong History of Bleeding. [PDF]

Biomolecules
Zamora-Cánovas A, Marín-Quílez A, Díaz-Ajenjo L, Sánchez-Fuentes A, Gómez-González PL, Crescente M, Fernández-Mosteirín N, Padilla J, González-Porras JR, Benito R, Lozano ML, Bastida JM, Rivera Pozo J.   +12 more
europepmc   +1 more source

Implementing a CYP2C19-guided approach for prescribing dual antiplatelet therapy in acute coronary syndrome for patients undergoing percutaneous coronary intervention: a cost-effectiveness analysis

Mahboub-Ahari A, Hilton J, Rodrigues M, McDermott J, Body R, Newman WG, Payne K.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The Function and Regulation of Platelet P2Y12 Receptor

Cardiovascular Drugs and Therapy, 2021
In addition to the key role in hemostasis and thrombosis, platelets have also been wildly acknowledged as immune regulatory cells and involving in the pathogenesis of inflammation-related diseases. Since purine receptor P2Y12 plays a crucial role in platelet activation, P2Y12 antagonists such as clopidogrel, prasugrel, and ticagrelor have been widely ...
Xia Cao
exaly   +3 more sources

P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor

Heart, 2021
Objective To compare P2Y12 inhibitor monotherapy after 3-month dual antiplatelet therapy (DAPT) with 12-month DAPT according to the type of P2Y12 inhibitor in patients undergoing percutaneous coronary intervention (PCI).
Juwon Kim, Woo Jin Jang, Wang Soo Lee, Ki Hong Choi, Joo Myung Lee, Taek Kyu Park, Jeong Hoon Yang, Jin-Ho Choi, Young Bin Song, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Sang Hoon Lee, Ju-Hyeon Oh, Woo Jung Chun, Yong Hwan Park, Eul-Soon Im, Jin-Ok Jeong, Byung Ryul Cho, Seok Kyu Oh, Kyeong Ho Yun, Deok-Kyu Cho, Jong-Young Lee, Young-Youp Koh, Jang-Whan Bae, Jae Woong Choi, Hyuck Jun Yoon, Seung Uk Lee, Jang Hyun Cho, Woong Gil Choi, Seung-Woon Rha, Joo-Yong Hahn   +30 more
openaire   +2 more sources

Selatogrel: A Novel Subcutaneous P2Y12 Inhibitor

Journal of Cardiovascular Pharmacology, 2022
Abstract: The use of a P2Y12 inhibitor as a component of dual antiplatelet therapy in patients with an acute coronary syndrome (ACS) is well established. However, the P2Y12 inhibitors currently available have pharmacokinetic limitations due to delayed absorption, lack of enteral access for administration with oral formulations, need for ...
Craig J, Beavers, Samuel Aaron, Effoe, Paul P, Dobesh   +2 more
openaire   +2 more sources

Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function

Thrombosis and Haemostasis, 2010
SummaryThe thienopyridine P2Y12 receptor antagonists clopidogrel and prasugrel prevent arterial thrombosis and are routinely used following percutaneous coronary intervention. However, the optimal level of P2Y12 blockade to effectively inhibit platelet function is unknown.
Robert J Buckland, Robert F Storey
exaly   +3 more sources

P2Y12 inhibitors

Hämostaseologie, 2009
SummaryThe P2Y12 receptor has proven to be a key target in the prevention of complications associated with atherosclerotic vascular disease especially in the context of acute coronary syndrome and percutaneous coronary intervention in addition to aspirin.
J-P, Collet, G, Montalescot
openaire   +2 more sources